Drug development challenges in polycythemia vera

Abstract

In this issue of Blood, Mascarenhas et al report on the safety and efficacy of oral idasanutlin in high-risk patients with polycythemia vera [PV]) with the goal of targeting hematopoietic stem cells and progenitor cells (HSC/HPCs) in this indolent malignancy